Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Total Current Liabilities of $71.0 million for Q1 2026, up 19.96% year-over-year from $59.2 million in Q1 2025, and up 10.63% quarter-over-quarter from $64.2 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $71.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 19.96% year-over-year to $71.0 million; the TTM figure through Mar 2026 stood at $71.0 million (up 19.96% YoY), while the FY2025 annual figure was $64.2 million, down 59.09% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $71.0 million, up from $64.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $156.9 million in Q4 2024, with the low at $12.5 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $41.6 million (2024), against an average of $44.9 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 236.85% in 2024, then plunged 59.09% in 2025.
- Monte Rosa Therapeutics' Total Current Liabilities stood at $25.6 million in 2022, then surged by 82.22% to $46.6 million in 2023, then soared by 236.85% to $156.9 million in 2024, then slumped by 59.09% to $64.2 million in 2025, then gained by 10.63% to $71.0 million in 2026.
- Business Quant data shows GLUE's Total Current Liabilities at $71.0 million in Q1 2026, $64.2 million in Q4 2025, and $61.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 59.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.66 Mn |
| Mar 31, 2026 | 71.04 Mn |
| Dec 31, 2025 | 64.21 Mn |
| Sep 30, 2025 | 61.44 Mn |
| Jun 30, 2025 | 41.85 Mn |
| Mar 31, 2025 | 59.22 Mn |
| Dec 31, 2024 | 156.95 Mn |
| Sep 30, 2024 | 41.64 Mn |
| Jun 30, 2024 | 42.35 Mn |
| Mar 31, 2024 | 41.29 Mn |
| Dec 31, 2023 | 46.59 Mn |
| Sep 30, 2023 | 22.61 Mn |
| Jun 30, 2023 | 19.09 Mn |
| Mar 31, 2023 | 20.52 Mn |
| Dec 31, 2022 | 25.57 Mn |
| Sep 30, 2022 | 21.79 Mn |
| Jun 30, 2022 | 14.77 Mn |
| Mar 31, 2022 | 12.49 Mn |
| Dec 31, 2021 | 16.64 Mn |
| Sep 30, 2021 | 12.74 Mn |